Novel Updates in Second-line Therapies for LR-MDS

Recent advancements in the treatment of lower-risk myelodysplastic syndrome (LR-MDS) have been discussed, focusing on the dose escalation of luspatercept. Insights from the MAXILUS trial (Della Porta et al, EHA 2024) and real-world evidence (Patel et al, EHA 2024) were highlighted, showcasing the potential of this dosing strategy to improve patient outcomes and influence clinical practice. The discussions emphasized the importance of these findings in enhancing patient care for those with LR-MDS, marking a significant step forward in the management of this condition.